Hermes Medical Solutions joins FNIH Biomarkers Consortium's Project to advance cancer treatments
Stockholm, Sweden—April 4, 2025—Hermes Medical Solutions is proud to announce its participation in the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium’s groundbreaking Precision Dosimetry Imaging Biomarker (PDIB) project. This ambitious international initiative seeks to transform radiopharmaceutical therapy (RPT) through improved dosimetry, leading to more effective and personalized cancer treatments.
As a leader in advanced medical imaging and dosimetry solutions, Hermes Medical Solutions brings cutting-edge expertise to the PDIB project, supporting the development of tools and methodologies that enhance radiation dose quantification. The company’s innovative software solutions enable precise, patient-specific dosimetry, helping to optimize therapeutic outcomes while minimizing adverse effects.
The PDIB project, a three-year, $4.9 million initiative, brings together a diverse consortium of experts from government agencies, academic institutions, medical societies, industry leaders, and advocacy groups. The project aims to establish standardized imaging protocols and reliable radiation dose measurements to ensure consistent and effective treatment strategies for patients undergoing RPT.
“We are proud to support the Biomarkers Consortium Precision Dosimetry Imaging Biomarker Project (PDIB) and look forward to collaborating with fellow industry leaders,” said Tom Francke, CEO at Hermes Medical Solutions. “We welcome the initiative to help develop a framework for development, standardization, and harmonization for quantitative RPT imaging and dosimetry.”
Through its involvement in PDIB, Hermes Medical Solutions will contribute to developing novel imaging-based dosimetry approaches that can accurately track and measure the delivery of RPTs. These advancements will help clinicians tailor treatments more effectively, leading to improved patient outcomes and broader adoption of RPTs in clinical practice.
About Hermes Medical Solutions
Hermes Medical Solutions continuously innovates to enable faster and more personalized diagnosis and therapies in molecular imaging. With Hermia, healthcare professionals are empowered with state-of-the-art software for all clinical scenarios into ONE truly vendor-neutral platform. Powerful tools enable clinicians to simplify their workflow and keep pace with the fast development of scanners, tracers and procedures in nuclear medicine. The result is improved quality in patient management and decision support for thousands of healthcare providers and their patients worldwide.
www.hermesmedical.com
About FNIH’s Biomarkers Consortium
Established by Congress in 1990 to support the mission of the National Institutes of Health (NIH), the Foundation for the NIH (FNIH) builds public-private partnerships that connect leading biomedical scientists at the NIH, life sciences companies, foundations, academia, and regulatory agencies. Through team science, we solve complex health challenges and accelerate breakthroughs for patients. The FNIH’s Biomarkers Consortium leads cross-sector efforts to validate and seek regulatory endorsement of biomarkers, make research results broadly available, and accelerate the development of new therapeutics and health technologies.
The FNIH is a not-for-profit 501(c)(3) charitable organization. For more information, please visit fnih.org.
Contact
Bridget Watson
Chief Marketing Officer
Hermes Medical Solutions AB (HQ)
Strandbergsgatan 16
112 51 Stockholm, Sweden
Tel: +46 76 076 47 28
bridget.watson@hermesmedical.com